News
ASRT
18.02
0.00%
0.00
Weekly Report: what happened at ASRT last week (0406-0410)?
Weekly Report · 1d ago
What Moved Markets This Week
Seeking Alpha · 3d ago
U.S. RESEARCH ROUNDUP-Chevron, Littelfuse, Parker-Hannifin
Reuters · 4d ago
ASSERTIO HOLDINGS INC <ASRT.O>: MAXIM GROUP CUTS TO HOLD FROM BUY
Reuters · 4d ago
Assertio downgraded to Hold from Buy at Maxim
TipRanks · 5d ago
Assertio Holdings Cut to Hold From Buy by Lake Street
Dow Jones · 5d ago
Assertio Holdings Price Target Cut to $18.00/Share From $45.00 by Lake Street
Dow Jones · 5d ago
Lake Street Downgrades Assertio Hldgs to Hold, Lowers Price Target to $18
Benzinga · 5d ago
This Zscaler Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Benzinga · 5d ago
Texas Instruments To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga · 5d ago
Assertio downgraded to Hold at Lake Street after takeover agreement
TipRanks · 5d ago
Assertio downgraded to Hold from Buy at Lake Street
TipRanks · 5d ago
Assertio to Be Acquired by Garda in Cash Deal
TipRanks · 5d ago
Assertio Holdings Price Target Cut to $18.00/Share From $35.00 by HC Wainwright & Co.
Dow Jones · 5d ago
Assertio Holdings Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 5d ago
HC Wainwright & Co. Downgrades Assertio Hldgs to Neutral, Lowers Price Target to $18
Benzinga · 5d ago
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL), Assertio Therapeutics (ASRT) and Alibaba Health Information Technology (OtherALBHF)
TipRanks · 5d ago
Assertio downgraded to Neutral from Buy at H.C. Wainwright
TipRanks · 5d ago
ASSERTIO HOLDINGS, INC. <ASRT.O>: H.C. WAINWRIGHT CUTS TO NEUTRAL FROM BUY
Reuters · 5d ago
U.S. RESEARCH ROUNDUP-Comstock Resources, Trustmark, Viasat
Reuters · 5d ago
More
Webull provides a variety of real-time ASRT stock news. You can receive the latest news about Assertio Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About ASRT
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.